Cystic Fibrosis Clinical Trials

44 studies are recruiting for cystic fibrosis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Boston, Massachusetts 11 Kansas City, Kansas 10 Philadelphia, Pennsylvania 10 Birmingham, Alabama 9 Cincinnati, Ohio 9 Seattle, Washington 8 Aurora, Colorado 7 Baltimore, Maryland 7 Dallas, Texas 7 Pittsburgh, Pennsylvania 7 St Louis, Missouri 7 Ann Arbor, Michigan 6 Atlanta, Georgia 6 Charleston, South Carolina 6 Denver, Colorado 6 Indianapolis, Indiana 6 Los Angeles, California 6 Portland, Oregon 6 Chapel Hill, North Carolina 5 New York, New York 5 Iowa City, Iowa 4 Madison, Wisconsin 4 Minneapolis, Minnesota 4 Nashville, Tennessee 4 Tucson, Arizona 4 Bethesda, Maryland 3 Boise, Idaho 3 Chicago, Illinois 3 Cleveland, Ohio 3 Columbus, Ohio 3 Fort Worth, Texas 3 Gainesville, Florida 3 Grand Rapids, Michigan 3 Hershey, Pennsylvania 3 Houston, Texas 3 Jacksonville, Florida 3 Miami, Florida 3 Orlando, Florida 3 Palo Alto, California 3 Richmond, Virginia 3 Salt Lake City, Utah 3 Spokane, Washington 3 Valhalla, New York 3

Studies, page 2

  1. A Study Assessing KB407 for the Treatment of Cystic Fibrosis

    This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Florida, Gainesville, Gainesville, Florida
    Locations
    6 in total
    Run by
    Krystal Biotech, Inc.

    See if you can join NCT05504837 on ClinicalTrials.gov

  2. Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

    The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.

    Stage
    Phase 1
    Ages
    3 and older
    Site
    University of Kansas Medical Center, Kansas City, Kansas
    Run by
    Mario Castro, MD, MPH

    See if you can join NCT04624490 on ClinicalTrials.gov

  3. Markers of Osteoporosis in Cystic Fibrosis

    Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study an…

    Stage
    Phase 4
    Ages
    18 to 64
    Site
    UT Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT03921060 on ClinicalTrials.gov

  4. Maralixibat in Patients With Cystic Fibrosis and Constipation

    Chronic constipation is common in children with cystic fibrosis (CF), likely due to impaired chloride channel function that reduces intestinal secretions. Standard osmotic laxatives often provide inadequate relief in this population. Maralixibat is an ileal bile acid transporter inhibitor (IBATi) t…

    Stage
    Phase 2
    Ages
    1 to 18
    Site
    Children's Hospital Los Angeles, Los Angeles, California
    Run by
    Children's Hospital Los Angeles

    See if you can join NCT06413368 on ClinicalTrials.gov

  5. Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

    The purpose of this study is to assess the efficacy of metformin to improve airway ion channel function in those with CF-related diabetes (CFRD)

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Kansas Medical Center, Kansas City, Kansas
    Run by
    University of Kansas Medical Center

    See if you can join NCT04530383 on ClinicalTrials.gov

  6. Personalized Theratyping Trial

    The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.

    Stage
    EARLY_Phase 1
    Ages
    6 and older
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Run by
    George Solomon

    See if you can join NCT03587961 on ClinicalTrials.gov

  7. Beta-cell Response to Incretin Hormones in Cystic Fibrosis

    In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. In…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania
    Run by
    University of Pennsylvania

    See if you can join NCT01851694 on ClinicalTrials.gov

  8. Regional Monitoring of CF Lung Disease

    The main reason for this research study is to learn more about some new tests that are being developing for patients with Cystic Fibrosis (CF) to measure changes in the lungs. In this study, the focus will be to learn how stopping Airway Clearance (ACT) and re-starting ACT can affect these tests. T…

    Stage
    EARLY_Phase 1
    Ages
    12 to 21
    Site
    Cincinnati Children's Hospital, Cincinnati, Ohio
    Run by
    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT06339593 on ClinicalTrials.gov

  9. Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)

    Cystic fibrosis (CF) is a multisystem autosomal recessive inherited disease affecting approximately 75,000 individuals in USA. The sweat chloride (Cl) test remains the gold standard for diagnosis of CF but still has a number of limitations. The objectives of this study are: 1)To evaluate a skin-int…

    Stage
    Not phased
    Ages
    18 to 80
    Site
    Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
    Run by
    Milton S. Hershey Medical Center

    See if you can join NCT05998629 on ClinicalTrials.gov

  10. Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials

    The purpose of this study is to validate and utilize a personalized medicine approach to identify potential treatments with current FDA approved CFTR modifiers for non-approved CF gene mutations. The study will perform ex vivo testing of CFTR function and current marketed CFTR modulating drugs on e…

    Stage
    Not phased
    Ages
    6 and older
    Site
    CCHMC, Cincinnati, Ohio
    Run by
    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT04580368 on ClinicalTrials.gov

  11. Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

    The goal of this observational study is to learn about the effects of a specific cystic fibrosis therapy (Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy) on chronic sinonasal disease. The main questions it aims to answer are: 1. How does this therapy impact bacterial communit…

    Stage
    Not phased
    Ages
    18 to 99
    Site
    Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
    Run by
    Dartmouth-Hitchcock Medical Center

    See if you can join NCT05982795 on ClinicalTrials.gov

  12. Estrogen Supplementation and Bone Health in Women With CF

    The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF). The study has two main components, an observational study and a feasibility sub-study. The main questions it aims to answer are: * How …

    Stage
    Phase 4
    Ages
    0 to 100
    Site
    Johns Hopkins, Baltimore, Maryland
    Run by
    Johns Hopkins University

    See if you can join NCT05704036 on ClinicalTrials.gov

  13. Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

    RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor …

    Stage
    Not phased
    Ages
    6 and older
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Locations
    18 in total
    Run by
    Boston Children's Hospital

    See if you can join NCT06683092 on ClinicalTrials.gov

  14. Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis

    The investigators will be evaluating bone marrow composition via magnetic resonance imaging in adolescents diagnosed with cystic fibrosis (CF) compared to healthy, matched controls. The investigators will also be assessing their bone mineral density via other imaging modalities, including dual-ener…

    Stage
    Not phased
    Ages
    13 to 20
    Site
    Boston Children's Hospital, Boston, Massachusetts
    Run by
    Massachusetts General Hospital

    See if you can join NCT06216704 on ClinicalTrials.gov

  15. A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

    The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to in…

    Stage
    Not phased
    Ages
    12 and older
    Site
    The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama
    Locations
    68 in total
    Run by
    Nicole Hamblett

    See if you can join NCT06504589 on ClinicalTrials.gov

  16. The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes

    This study will evalute the effect of a low glycemic load (LGL diet on dysglycemia, insulin requirements, DXA-derived body composition, gastrointestinal symptoms and quality of life measures in adults with cystic fibrosis-related diabetes (CFRD). We will use continuous glucose monitors (CGM) to ass…

    Stage
    Not phased
    Ages
    18 to 70
    Site
    Boston Children's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Rhode Island Hospital

    See if you can join NCT05723445 on ClinicalTrials.gov

  17. Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

    The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator therapy. Participants wil…

    Stage
    Phase 2
    Ages
    12 and older
    Site
    University of Kansas Medical Center, Kansas City, Kansas
    Run by
    University of Kansas Medical Center

    See if you can join NCT06364176 on ClinicalTrials.gov

  18. Lung Transplant READY CF 2: CARING CF Ancillary RCT

    Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In the United States, more people with CF and low lung function die each year than undergo lung transplant. More than half of people with CF who die without a lung transplant were never referred for considerat…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Washington Medical Center - Montlake, Seattle, Washington
    Run by
    University of Washington

    See if you can join NCT06032273 on ClinicalTrials.gov

  19. A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

    This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.

    Stage
    Phase 1
    Ages
    18 to 65
    Site
    University of Kansas Medical Center, Kansas City, Kansas
    Locations
    4 in total
    Run by
    Spirovant Sciences, Inc.

    See if you can join NCT06526923 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.